Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis [Phase 3]

View source ↗

Summary

Phase 3 study of paricalcitol capsules in End-stage renal disease patients on peritoneal dialysis has completed. The document updates the trial evaluating safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Zemplar (paricalcitol) (paricalcitol)

Snippet

Sponsor: Abbott | Conditions: End Stage Renal Disease | Phase 3 | Status: COMPLETED